Mukarram Anees (2008-VA-537)
Formulation And In-Vitro Evaluation Of Polymers Blend Based Diclofenac Microparticles For Sustained Release Drug Delivery - 2015. - 69p.;
Diclofenac Sodium is a nonsteroidal anti-inflammatory drug with plasma half life (t1/2) of 1-2 hours. It is used as anti-inflammatory and analgesic in joint pain, ankylosing spondylitis and osteoarthritis for a long duration of time. Diclofenac Sodium conventional oral dosage forms have drawbacks of repeated administration (2-3 times/day) and GIT side effects. Diclofenac Sodium microparticles were prepared with ethyl cellulose and starch blend. Emulsification and solvent evaporation method was selected which was easy to perform. Starch was selected in view of its increased hydrophilicity, bio-compatibility and bio-degradability. Ethylcellulose was selected for reason of increased hydrophobicity, bio-compatibility and non-biodegradability.
Three formulations were prepared with different proportions of polymers (ethyl cellulose and starch). Micromeritic studies, particle size, percentage loading efficiency and invitro release studies with application of kinetic models were evaluated. Formulation D3 gave the best results due to increased amount of ethyl cellulose and decreased amount of starch. Polymeric blend resulted in sustained release effect. FT-IR studies were conducted to check the possible drug-polymer interaction. There was no significant drug-polymer interaction was seen. Formulation D3 showed 51.25 % in-vitro drug release up to 8 hours and followed Higuchi and Korsmeyer-Peppas model. The ‘n’ value indicated that it followed Fickian diffusion.
After characterization of Diclofenac Sodium microparticles, the findings elaborated that polymeric blend (synthetic and natural) can be used to achieve sustained release effect due to their distinct characteristics. However, a suitable combination of polymers (75:25 ratio of EC: Starch) is necessary to achieve desired effects. Diclofenac Sodium microparticles can be used to reduce side effects and increase the patient compliance.
Department of Pharmaceutics
2398-T
Formulation And In-Vitro Evaluation Of Polymers Blend Based Diclofenac Microparticles For Sustained Release Drug Delivery - 2015. - 69p.;
Diclofenac Sodium is a nonsteroidal anti-inflammatory drug with plasma half life (t1/2) of 1-2 hours. It is used as anti-inflammatory and analgesic in joint pain, ankylosing spondylitis and osteoarthritis for a long duration of time. Diclofenac Sodium conventional oral dosage forms have drawbacks of repeated administration (2-3 times/day) and GIT side effects. Diclofenac Sodium microparticles were prepared with ethyl cellulose and starch blend. Emulsification and solvent evaporation method was selected which was easy to perform. Starch was selected in view of its increased hydrophilicity, bio-compatibility and bio-degradability. Ethylcellulose was selected for reason of increased hydrophobicity, bio-compatibility and non-biodegradability.
Three formulations were prepared with different proportions of polymers (ethyl cellulose and starch). Micromeritic studies, particle size, percentage loading efficiency and invitro release studies with application of kinetic models were evaluated. Formulation D3 gave the best results due to increased amount of ethyl cellulose and decreased amount of starch. Polymeric blend resulted in sustained release effect. FT-IR studies were conducted to check the possible drug-polymer interaction. There was no significant drug-polymer interaction was seen. Formulation D3 showed 51.25 % in-vitro drug release up to 8 hours and followed Higuchi and Korsmeyer-Peppas model. The ‘n’ value indicated that it followed Fickian diffusion.
After characterization of Diclofenac Sodium microparticles, the findings elaborated that polymeric blend (synthetic and natural) can be used to achieve sustained release effect due to their distinct characteristics. However, a suitable combination of polymers (75:25 ratio of EC: Starch) is necessary to achieve desired effects. Diclofenac Sodium microparticles can be used to reduce side effects and increase the patient compliance.
Department of Pharmaceutics
2398-T